StockNews.com Downgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Sell

StockNews.com downgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a hold rating to a sell rating in a report published on Monday.

Several other analysts have also weighed in on AGIO. The Goldman Sachs Group upped their price objective on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a report on Tuesday, June 4th. Royal Bank of Canada lifted their price objective on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the stock an outperform rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. reiterated a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. Finally, Cantor Fitzgerald restated an overweight rating on shares of Agios Pharmaceuticals in a report on Monday, June 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus target price of $51.33.

Agios Pharmaceuticals Stock Up 2.9 %

AGIO stock opened at $43.79 on Monday. Agios Pharmaceuticals has a fifty-two week low of $19.80 and a fifty-two week high of $50.35. The company has a market capitalization of $2.49 billion, a P/E ratio of -6.93 and a beta of 0.79. The company has a 50-day simple moving average of $45.00 and a 200 day simple moving average of $35.06.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 44.84%. Agios Pharmaceuticals’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.51) EPS. Equities analysts anticipate that Agios Pharmaceuticals will post -2.15 EPS for the current year.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Agios Pharmaceuticals by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,934 shares of the biopharmaceutical company’s stock worth $867,000 after acquiring an additional 1,437 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Agios Pharmaceuticals by 9.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,444 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 942 shares in the last quarter. Handelsbanken Fonder AB raised its stake in Agios Pharmaceuticals by 31.8% during the 4th quarter. Handelsbanken Fonder AB now owns 12,023 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 2,900 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in shares of Agios Pharmaceuticals by 18.9% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 112,726 shares of the biopharmaceutical company’s stock valued at $2,510,000 after purchasing an additional 17,954 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Agios Pharmaceuticals by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 456,394 shares of the biopharmaceutical company’s stock valued at $10,164,000 after purchasing an additional 4,699 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.